Cervical cancer prevention in low- and middle-income countries: Feasible, affordable, essential

Cancer Prevention Research

Volumn 5, Issue 1, 2012, Pages 11-17

  Sahasrabuddhe, Vikrant V ^a,b   Parham, Groesbeck P ^c,d   Mwanahamuntu, Mulindi H ^d   Vermund, Sten H ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MIXED INFECTION; PAPANICOLAOU TEST; PELVIC EXAMINATION; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SCALE UP; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HIV INFECTIONS; HUMANS; MEDICAL ONCOLOGY; PAPILLOMAVIRUS INFECTIONS; POVERTY; PREVENTIVE MEDICINE; RISK; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; WORLD HEALTH;

EID: 84855560249     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0540     Document Type: Short Survey

References (65)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84.
4. Kane MA. Preventing cancer with vaccines: Progress in the global control of cancer. Cancer Prev Res 2012;5:24-9.
5. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res 2012;5:18-23.
6. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med 1997;121:211-24.
7. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 2006;24Suppl 3:S3/63-70.
8. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001;79:954-62. (Pubitemid 33027175)
9. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008;5:e132.
10. Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011;113:14-24.
11. Sahasrabuddhe VV, Bhosale RA, Kavatkar AN, Nagwanshi CA, Joshi SN, Jenkins CA, et al. Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India. Int J Cancer 2012;130:234-40.
12. Sankaranarayanan R, Nessa A, Esmy PO, Dangou JM. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2011 Nov 8. [Epub ahead of print].
13. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398-406. (Pubitemid 47176655)
14. Sankaranarayanan R, Rajkumar R, Esmy PO, Fayette JM, Shanthakumary S, Frappart L, et al. Effectiveness, safety and acceptability of 'see and treat' with cryotherapy by nurses in a cervical screening study in India. Br J Cancer 2007;96:738-43. (Pubitemid 46376636)
15. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med 2011;8:e1001032.
16. Pfaendler KS, Mwanahamuntu MH, Sahasrabuddhe VV, Mudenda V, Stringer JS, Parham GP. Management of cryotherapy-ineligible women in a "screen-and- treat" cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field. Gynecol Oncol 2008;110:402-7.
17. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
18. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
19. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
20. Yang HP, Walmer DK, Merisier D, Gage JC, Bell L, Rangwala S, et al. A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. J Virol Methods 2011;176:112-4.
21. Wiwanitkit V. Screening for cervical cancer: which common technique is the most cost-effective choice? Asian Pac J Cancer Prev 2009;10:531-2.
22. Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ 2005;83:186-94. (Pubitemid 40387158)
23. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26 Suppl 10:K29-41.
24. Goldhaber-Fiebert JD, Denny LA, De Souza M, Kuhn L, Goldie SJ. Program spending to increase adherence: South African cervical cancer screening. PLoS One 2009;4:e5691.
25. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-68. (Pubitemid 41653107)
26. Vanni T, Luz PM, Grinsztejn B, Veloso VG, Foss A, Mesa-Frias M, et al. Cervical cancer screening among HIV-infected women: An economic evaluation in a middle-income country. Int J Cancer 2011 Sep 30 [Epub ahead of print].
27. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008;99:230-8.
28. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2011 Jun 29 [Epub ahead of print].
29. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis 2007;45:510-3. (Pubitemid 47204472)
30. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 2010;5:8.
31. Behbahani H, Walther-Jallow L, Klareskog E, Baum L, French AL, Patterson BK, et al. Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr 2007;45:9-19. (Pubitemid 46684438)
32. Mkhize NN, Gumbi PP, Liebenberg LJ, Ren Y, Smith P, Denny L, et al. Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy. J Virol 2010;84:10765-72.
33. Henning TR, Kissinger P, Lacour N, Meyaski-Schluter M, Clark R, Amedee AM. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. J Infect Dis 2010;202:1543-52.
34. Hirbod T, Nilsson J, Andersson S, Uberti-Foppa C, Ferrari D, Manghi M, et al. Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr 2006;43:137-43. (Pubitemid 44454806)
35. Fitzgerald DW, Bezak K, Ocheretina O, et al. The effect of HIV and HPV co-infection on cervical COX-2 expression and systemic prostaglandin E2 Levels. Cancer Prev Res 2012;5:34-40.
36. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377-86.
37. Chan AT. Aspirin and familial adenomatous polyposis: coming full circle. Cancer Prev Res 2011;4:623-7.
38. Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 2011;12:1023-31.
39. Marks M, Gravitt PE, Gupta SB, Liaw KL, Tadesse A, Kim E, et al. Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis 2011;204:1505-13.
40. Al-Daraji WI, Smith JH. Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol 2009;2:48-64.
41. Zehbe I, Richard C, Lee KF, Campbell M, Hampson L, Hampson IN. Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antiviral Res 2011;91:161-6.
42. Roberts JN, Kines RC, Katki HA, Lowy DR, Schiller JT. Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst 2011;103:737-43.
43. Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, et al. Topical treatment of CIN 2 +by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 2009;115:69-74.
44. Auvert B, Marais D, Lissouba P, Zarca K, Ramjee G, Williamson AL. High-risk human papillomavirus is associated with HIV acquisition among South African female sex workers. Infect Dis Obstet Gynecol 2011;2011:692012.
45. van der Loeff MF, Nyitray AG, Giuliano AR. HPV vaccination to prevent HIV infection: time for randomized controlled trials. Sex Transm Dis 2011;38:640-3.
46. Taylor S, Wang C, Wright TC, Denny L, Tsai WY, Kuhn L. Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa. BMC Med 2010;8:40.
47. Tate DR, Anderson RJ. Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis. Am J Obstet Gynecol 2002;186:880-2.
48. Chung MH, McKenzie KP, Richardson BA, John-Stewart GC, Coombs RW, De Vuyst H, et al. Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3. AIDS 2011;25:1915-9.
49. Gage JC, Castle PE. Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst 2010;102:1524-7.
50. Teguete I, Muwonge R, Traore C, Dolo A, Bayo S, Sankaranarayanan R. Can visual cervical screening be sustained in routine health services? Experience from Mali, Africa. BJOG 2011 Sep 6 [Epub ahead of print].
51. Mutyaba T, Mirembe F, Sandin S, Weiderpass E. Evaluation of 'see-see and treat' strategy and role of HIV on cervical cancer prevention in Uganda. Reprod Health 2010;7:4.
52. Parham GP, Mwanahamuntu MH, Sahasrabuddhe VV, Westfall AO, King KE, Chibwesha C., et al. Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness. HIV Ther 2010;4:713-22.
53. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mudenda V, Hicks ML, Vermund SH, et al. Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS 2009;23:N1-5.
54. Parham GP, Mwanahamuntu MH, Pfaendler KS, Sahasrabuddhe VV, Myung D, Mkumba G, et al. eC3-a modern telecommunications matrix for cervical cancer prevention in Zambia. J Low Genit Tract Dis 2010;14:167-73.
55. Castellsague X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009;115:S15-23.
56. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15. (Pubitemid 43338210)
57. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JS, et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007;96:1480-3. (Pubitemid 46685795)
58. Bollen LJ, Chuachoowong R, Kilmarx PH, Mock PA, Culnane M, Skunodom N, et al. Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization. Sex Transm Dis 2006;33:259-64.
59. Rotheram-Borus MJ, Swendeman D, Chovnick G. The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 2009;5:143-67.
60. Buchbinder S. HIV epidemiology, testing strategies, and prevention interventions. Top HIV Med 2010;18:38-44.
61. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011;8:62-72.
62. Matovu JK. Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res 2010;8:430-40.
63. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010;51:725-31.
64. Vermund SH, Allen KL, Karim QA. HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS 2009;4:266-73.
65. Stanley M. Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 2008;20:388-94.